Autoimmune Disorders - Pipeline Review
H1 2013

Autoimmune Disorders - Pipeline Review H1 2013

Autoimmune Disorders - Pipeline Review, H1 2013

Summary

Global Markets Direct's, 'Autoimmune Disorders - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autoimmune Disorders. Autoimmune Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• A snapshot of the global therapeutic scenario for Autoimmune Disorders.
• A review of the Autoimmune Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Autoimmune Disorders pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Autoimmune Disorders.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Autoimmune Disorders pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

• Introduction
  • Global Markets Direct Report Coverage
  • Autoimmune Disorders Overview
• Therapeutics Development
  • An Overview of Pipeline Products for Autoimmune Disorders
  • Autoimmune Disorders Therapeutics under Development by Companies
  • Autoimmune Disorders Therapeutics under Investigation by Universities/Institutes
  • Late Stage Products
  • Comparative Analysis
  • Mid Clinical Stage Products
  • Comparative Analysis
  • Early Clinical Stage Products
  • Comparative Analysis
  • Discovery and Pre-Clinical Stage Products
  • Comparative Analysis
  • Autoimmune Disorders Therapeutics - Products under Development by Companies
  • Autoimmune Disorders Therapeutics - Products under Investigation by Universities/Institutes
• Companies Involved in Autoimmune Disorders Therapeutics Development
  • Alcon, Inc.
  • Johnson & Johnson
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Kyowa Hakko Kirin Co., Ltd.
  • Amgen Inc.
  • Antares Pharma, Inc.
  • Sanofi-Aventis
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • MedImmune LLC
  • Biotest AG
  • Merck & Co., Inc.
  • Ablynx
  • AbGenomics International, Inc.
  • Emergent BioSolutions Inc.
  • Novo Nordisk A/S
  • BioLineRx, Ltd.
  • MediGene AG
  • Nycomed International Management GmbH
  • TiGenix NV
  • Actelion Ltd
  • Astellas Pharma Inc.
  • Biocon Limited
  • Eisai Co., Ltd.
  • Elan Corporation, plc
  • Glenmark Pharmaceuticals Ltd.
  • GTC Biotherapeutics, Inc.
  • Japan Tobacco Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • LEO Pharma A/S
  • Pfizer Inc.
  • Rigel Pharmaceuticals, Inc.
  • Santarus, Inc.
  • Teva Pharmaceutical Industries Limited
  • UCB Group
  • Genmab A/S
  • Hadasit Medical Research Services & Development Ltd
  • Exelixis, Inc.
  • Celgene Corporation
  • Onyx Pharmaceuticals, Inc.
  • Incyte Corporation
  • Merck KGaA
  • 4SC AG
  • Evotec Aktiengesellschaft
  • Genesis Research and Development Corporation Ltd.
  • Hollis-Eden Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • Momenta Pharmaceuticals, Inc.
  • Active Biotech AB
  • IMMUNOMEDICS, INC
  • Idera Pharmaceuticals, Inc.
  • Karo Bio
  • Almirall, S.A.
  • NexMed, Inc.
  • Cleveland BioLabs, Inc.
  • Compugen Ltd.
  • Ore Pharmaceuticals Inc
  • Pharmos Corporation
  • Accentia Biopharmaceuticals, Inc.
  • Arena Pharmaceuticals, Inc.
  • Portola Pharmaceuticals, Inc.
  • Chelsea Therapeutics, Inc.
  • KOLON LIFE SCIENCE INC.
  • NeoStem, Inc.
  • Pharmacyclics, Inc.
  • Protalix BioTherapeutics, Inc.
  • Dynavax Technologies Corporation
  • Tolerx, Inc.
  • ProMetic Life Sciences Inc.
  • XOMA Ltd.
  • Antisoma plc
  • Transgene SA
  • Hanall Pharmaceutical Co., Ltd.
  • Panacea Biotec Limited
  • Catalyst Biosciences, Inc.
  • Innate Pharma SA
  • DiaMedica Inc.
  • Hansa Medical AB
  • R-Tech Ueno, Ltd.
  • Cellerant Therapeutics, Inc.
  • University of Erlangen-Nurnberg
  • Morphotek, Inc.
  • Affitech A/S
  • Debiopharm Group
  • Advinus Therapeutics Pvt. Ltd.
  • Axxam SpA
  • Alba Therapeutics Corporation
  • Ambit Biosciences Corporation
  • Viron Therapeutics, Inc.
  • Deltanoid Pharmaceuticals Inc.
  • Immupharma Plc
  • Palau Pharma S.A
  • Memgen, LLC.
  • Molecular Partners AG
  • Pieris AG
  • Phenex Pharmaceuticals AG
  • conoGenetix biosciences GmbH
  • Hutchison MediPharma Limited
  • CREABILIS Therapeutics S.r.l.
  • ERYtech Pharma
  • Affibody AB
  • Argos Therapeutics, Inc.
  • Aegera Therapeutics Inc.
  • Alligator Bioscience AB
  • Altor BioScience Corporation
  • Anacor Pharmaceuticals, Inc.
  • AnaptysBio, Inc.
  • Telormedix SA
  • Therapeutics Incorporated
  • Allozyne, Inc.
  • ZaBeCor Pharmaceuticals
  • Chiome Bioscience, Inc.
  • MacroGenics, Inc.
  • Recoly N.V.
  • Astion Pharma A/S
  • Five Prime Therapeutics, Inc.
  • Vaccinex, Inc.
  • Pantarhei Bioscience BV
  • Kineta, Inc.
  • Deciphera Pharmaceuticals, LLC
  • MSM Protein Technologies, Inc.
  • Reata Pharmaceuticals, Inc.
  • Vascular Biogenics Ltd.
  • Xention Limited
  • TcL Pharma SAS
  • Biotica Technology Ltd
  • VLST Corporation, Inc.
  • Virobay Inc.
  • NKT Therapeutics, Inc.
  • Omeros Corporation
  • The Scripps Research Institute
  • Xencor, Inc.
  • Cornerstone Therapeutics Inc.
  • SBI Biotech Co., Ltd.
  • iBio, Inc.
  • ChemoCentryx, Inc.
  • 4-Antibody AG
  • CBio Limited
  • VentiRx Pharmaceuticals, Inc.
  • Anthera Pharmaceuticals, Inc.
  • Biokine Therapeutics Ltd.
  • KYORIN Pharmaceutical Co., Ltd.
  • Avesthagen Limited
  • Maruho Co.,Ltd.
  • KAHR medical Ltd.
  • SuppreMol GmbH
  • NasVax Ltd.
  • Centocor Ortho Biotech, Inc.
  • AIMM Therapeutics B.V.
  • Zymeworks Inc.
  • Anaphore, Inc.
  • Dynamix Pharmaceuticals Ltd.
  • Amplimmune, Inc.
  • Lycera Corp.
  • Perseid Therapeutics LLC
  • LFB Biotechnologies, S.A.S.U.
  • Interprotein Corporation
  • CalciMedica, Inc.
  • Zyngenia, Inc.
  • MicroDose Therapeutx, Inc.
  • Bio Sidus S.A.
  • Gliknik, Inc.
  • XBiotech USA, Inc.
  • RaQualia Pharma Inc.
  • Advancell
  • Autoimmune Disorders
• Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Drug Profiles
  • forigerimod - Drug Profile
  • brodalumab - Drug Profile
  • ixekizumab - Drug Profile
  • tabalumab - Drug Profile
  • tofacitinib - Drug Profile
  • belimumab - Drug Profile
  • apremilast - Drug Profile
  • secukinumab - Drug Profile
  • tocilizumab - Drug Profile
  • certolizumab pegol - Drug Profile
  • blisibimod - Drug Profile
  • ustekinumab - Drug Profile
  • epratuzumab - Drug Profile
  • methotrexate - Drug Profile
  • tildrakizumab - Drug Profile
  • immune globulin intravenous (human) - Drug Profile
  • LAS-41008 - Drug Profile
  • Autoimmune Disorders Therapeutics - Drug Profile Updates
  • Autoimmune Disorders Therapeutics - Discontinued Products
  • Autoimmune Disorders Therapeutics - Dormant Products
  • Autoimmune Disorders - Product Development Milestones
• Featured News & Press Releases
• Appendix
• Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • R&D Progress
• Disclaimer
• List of Tables
  • Number of Products Under Development for Autoimmune Disorders, H1 2013
  • Products under Development for Autoimmune Disorders - Comparative Analysis, H1 2013
  • Number of Products under Development by Companies, H1 2013
  • Number of Products under Development by Companies, H1 2013 (Contd..1)
  • Number of Products under Development by Companies, H1 2013 (Contd..2)
  • Number of Products under Development by Companies, H1 2013 (Contd..3)
  • Number of Products under Development by Companies, H1 2013 (Contd..4)
  • Number of Products under Development by Companies, H1 2013 (Contd..5)
  • Number of Products under Development by Companies, H1 2013 (Contd..6)
  • Number of Products under Development by Companies, H1 2013 (Contd..7)
  • Number of Products under Development by Companies, H1 2013 (Contd..8)
  • Number of Products under Development by Companies, H1 2013 (Contd..9)
  • Number of Products under Development by Companies, H1 2013 (Contd..10)
  • Number of Products under Development by Companies, H1 2013 (Contd..11)
  • Number of Products under Development by Companies, H1 2013 (Contd..12)
  • Number of Products under Development by Companies, H1 2013 (Contd..13)
  • Number of Products under Investigation by Universities/Institutes, H1 2013
  • Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1)
  • Comparative Analysis by Late Stage Development, H1 2013
  • Comparative Analysis by Mid Clinical Stage Development, H1 2013
  • Comparative Analysis by Early Clinical Stage Development, H1 2013
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
  • Products under Development by Companies, H1 2013
  • Products under Development by Companies, H1 2013 (Contd..1)
  • Products under Development by Companies, H1 2013 (Contd..2)
  • Products under Development by Companies, H1 2013 (Contd..3)
  • Products under Development by Companies, H1 2013 (Contd..4)
  • Products under Development by Companies, H1 2013 (Contd..5)
  • Products under Development by Companies, H1 2013 (Contd..6)
  • Products under Development by Companies, H1 2013 (Contd..7)
  • Products under Development by Companies, H1 2013 (Contd..8)
  • Products under Development by Companies, H1 2013 (Contd..9)
  • Products under Development by Companies, H1 2013 (Contd..10)
  • Products under Development by Companies, H1 2013 (Contd..11)
  • Products under Development by Companies, H1 2013 (Contd..12)
  • Products under Development by Companies, H1 2013 (Contd..13)
  • Products under Development by Companies, H1 2013 (Contd..14)
  • Products under Development by Companies, H1 2013 (Contd..15)
  • Products under Development by Companies, H1 2013 (Contd..16)
  • Products under Development by Companies, H1 2013 (Contd..17)
  • Products under Development by Companies, H1 2013 (Contd..18)
  • Products under Development by Companies, H1 2013 (Contd..19)
  • Products under Development by Companies, H1 2013 (Contd..20)
  • Products under Investigation by Universities/Institutes, H1 2013
  • Products under Investigation by Universities/Institutes, H1 2013 (Contd..1)
  • Alcon, Inc., H1 2013
  • Johnson & Johnson, H1 2013
  • Boehringer Ingelheim GmbH, H1 2013
  • F. Hoffmann-La Roche Ltd., H1 2013
  • Kyowa Hakko Kirin Co., Ltd., H1 2013
  • Amgen Inc., H1 2013
  • Antares Pharma, Inc., H1 2013
  • Sanofi-Aventis, H1 2013
  • Eli Lilly and Company, H1 2013
  • GlaxoSmithKline plc, H1 2013
  • Genentech, Inc., H1 2013
  • MedImmune LLC, H1 2013
  • Biotest AG, H1 2013
  • Merck & Co., Inc., H1 2013
  • Ablynx, H1 2013
  • AbGenomics International, Inc., H1 2013
  • Emergent BioSolutions Inc., H1 2013
  • Novo Nordisk A/S, H1 2013
  • BioLineRx, Ltd., H1 2013
  • MediGene AG, H1 2013
  • Nycomed International Management GmbH, H1 2013
  • TiGenix NV, H1 2013
  • Actelion Ltd, H1 2013
  • Astellas Pharma Inc., H1 2013
  • Biocon Limited, H1 2013
  • Eisai Co., Ltd., H1 2013
  • Elan Corporation, plc, H1 2013
  • Glenmark Pharmaceuticals Ltd., H1 2013
  • GTC Biotherapeutics, Inc., H1 2013
  • Japan Tobacco Inc., H1 2013
  • Kissei Pharmaceutical Co., Ltd., H1 2013
  • LEO Pharma A/S, H1 2013
  • Pfizer Inc., H1 2013
  • Rigel Pharmaceuticals, Inc., H1 2013
  • Santarus, Inc., H1 2013
  • Teva Pharmaceutical Industries Limited, H1 2013
  • UCB Group, H1 2013
  • Genmab A/S, H1 2013
  • Hadasit Medical Research Services & Development Ltd, H1 2013
  • Exelixis, Inc., H1 2013
  • Celgene Corporation, H1 2013
  • Onyx Pharmaceuticals, Inc., H1 2013
  • Incyte Corporation, H1 2013
  • Merck KGaA, H1 2013
  • 4SC AG, H1 2013
  • Evotec Aktiengesellschaft, H1 2013
  • Genesis Research and Development Corporation Ltd., H1 2013
  • Hollis-Eden Pharmaceuticals, Inc., H1 2013
  • Celldex Therapeutics, Inc., H1 2013
  • Momenta Pharmaceuticals, Inc., H1 2013
  • Active Biotech AB, H1 2013
  • IMMUNOMEDICS, INC, H1 2013
  • Idera Pharmaceuticals, Inc., H1 2013
  • Karo Bio, H1 2013
  • Almirall, S.A., H1 2013
  • NexMed, Inc., H1 2013
  • Cleveland BioLabs, Inc., H1 2013
  • Compugen Ltd., H1 2013
  • Ore Pharmaceuticals Inc, H1 2013
  • Pharmos Corporation, H1 2013
  • Accentia Biopharmaceuticals, Inc., H1 2013
  • Arena Pharmaceuticals, Inc., H1 2013
  • Portola Pharmaceuticals, Inc., H1 2013
  • Chelsea Therapeutics, Inc., H1 2013
  • KOLON LIFE SCIENCE INC., H1 2013
  • NeoStem, Inc., H1 2013
  • Pharmacyclics, Inc., H1 2013
  • Protalix BioTherapeutics, Inc., H1 2013
  • Dynavax Technologies Corporation, H1 2013
  • Tolerx, Inc., H1 2013
  • ProMetic Life Sciences Inc., H1 2013
  • XOMA Ltd., H1 2013
  • Antisoma plc, H1 2013
  • Transgene SA, H1 2013
  • Hanall Pharmaceutical Co., Ltd., H1 2013
  • Panacea Biotec Limited, H1 2013
  • Catalyst Biosciences, Inc., H1 2013
  • Innate Pharma SA, H1 2013
  • DiaMedica Inc., H1 2013
  • Hansa Medical AB, H1 2013
  • R-Tech Ueno, Ltd., H1 2013
  • Cellerant Therapeutics, Inc., H1 2013
  • University of Erlangen-Nurnberg, H1 2013
  • Morphotek, Inc., H1 2013
  • Affitech A/S, H1 2013
  • Debiopharm Group, H1 2013
  • Advinus Therapeutics Pvt. Ltd., H1 2013
  • Axxam SpA, H1 2013
  • Alba Therapeutics Corporation, H1 2013
  • Ambit Biosciences Corporation, H1 2013
  • Viron Therapeutics, Inc., H1 2013
  • Deltanoid Pharmaceuticals Inc., H1 2013
  • Immupharma Plc, H1 2013
  • Palau Pharma S.A, H1 2013
  • Memgen, LLC., H1 2013
  • Molecular Partners AG, H1 2013
  • Pieris AG, H1 2013
  • Phenex Pharmaceuticals AG, H1 2013
  • conoGenetix biosciences GmbH, H1 2013
  • Hutchison MediPharma Limited, H1 2013
  • CREABILIS Therapeutics S.r.l., H1 2013
  • ERYtech Pharma, H1 2013
  • Affibody AB, H1 2013
  • Argos Therapeutics, Inc., H1 2013
  • Aegera Therapeutics Inc., H1 2013
  • Alligator Bioscience AB, H1 2013
  • Altor BioScience Corporation, H1 2013
  • Anacor Pharmaceuticals, Inc., H1 2013
  • AnaptysBio, Inc., H1 2013
  • Telormedix SA, H1 2013
  • Therapeutics Incorporated, H1 2013
  • Allozyne, Inc., H1 2013
  • ZaBeCor Pharmaceuticals, H1 2013
  • Chiome Bioscience, Inc., H1 2013
  • MacroGenics, Inc., H1 2013
  • Recoly N.V., H1 2013
  • Astion Pharma A/S, H1 2013
  • Five Prime Therapeutics, Inc., H1 2013
  • Vaccinex, Inc., H1 2013
  • Pantarhei Bioscience BV, H1 2013
  • Kineta, Inc., H1 2013
  • Deciphera Pharmaceuticals, LLC, H1 2013
  • MSM Protein Technologies, Inc., H1 2013
  • Reata Pharmaceuticals, Inc., H1 2013
  • Vascular Biogenics Ltd., H1 2013
  • Xention Limited, H1 2013
  • TcL Pharma SAS, H1 2013
  • Biotica Technology Ltd, H1 2013
  • VLST Corporation, Inc., H1 2013
  • Virobay Inc., H1 2013
  • NKT Therapeutics, Inc., H1 2013
  • Omeros Corporation, H1 2013
  • The Scripps Research Institute, H1 2013
  • Xencor, Inc., H1 2013
  • Cornerstone Therapeutics Inc., H1 2013
  • SBI Biotech Co., Ltd., H1 2013
  • iBio, Inc., H1 2013
  • ChemoCentryx, Inc., H1 2013
  • 4-Antibody AG, H1 2013
  • CBio Limited, H1 2013
  • VentiRx Pharmaceuticals, Inc., H1 2013
  • Anthera Pharmaceuticals, Inc., H1 2013
  • Biokine Therapeutics Ltd., H1 2013
  • KYORIN Pharmaceutical Co., Ltd., H1 2013
  • Avesthagen Limited, H1 2013
  • Maruho Co.,Ltd., H1 2013
  • KAHR medical Ltd., H1 2013
  • SuppreMol GmbH, H1 2013
  • NasVax Ltd., H1 2013
  • Centocor Ortho Biotech, Inc., H1 2013
  • AIMM Therapeutics B.V., H1 2013
  • Zymeworks Inc., H1 2013
  • Anaphore, Inc., H1 2013
  • Dynamix Pharmaceuticals Ltd., H1 2013
  • Amplimmune, Inc., H1 2013
  • Lycera Corp., H1 2013
  • Perseid Therapeutics LLC, H1 2013
  • LFB Biotechnologies, S.A.S.U., H1 2013
  • Interprotein Corporation, H1 2013
  • CalciMedica, Inc., H1 2013
  • Zyngenia, Inc., H1 2013
  • MicroDose Therapeutx, Inc., H1 2013
  • Bio Sidus S.A., H1 2013
  • Gliknik, Inc., H1 2013
  • XBiotech USA, Inc., H1 2013
  • RaQualia Pharma Inc., H1 2013
  • Advancell, H1 2013
  • Assessment by Monotherapy Products, H1 2013
  • Assessment by Combination Products, H1 2013
  • Assessment by Stage and Route of Administration, H1 2013
  • Assessment by Stage and Molecule Type, H1 2013
  • Autoimmune Disorders Therapeutics - Drug Profile Updates
  • Autoimmune Disorders Therapeutics - Discontinued Products
  • Autoimmune Disorders Therapeutics - Discontinued Products (Contd..1)
  • Autoimmune Disorders Therapeutics - Dormant Products
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..1)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..2)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..3)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..4)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..5)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..6)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..7)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..8)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..9)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..10)
  • Autoimmune Disorders Therapeutics - Dormant Products (Contd..11)
• List of Figures
  • Number of Products under Development for Autoimmune Disorders, H1 2013
  • Products under Development for Autoimmune Disorders - Comparative Analysis, H1 2013
  • Products under Development by Companies, H1 2013
  • Products under Investigation by Universities/Institutes, H1 2013
  • Late Stage Products, H1 2013
  • Mid Clinical Stage Products, H1 2013
  • Early Clinical Stage Products, H1 2013
  • Discovery and Pre-Clinical Stage Products, H1 2013
  • Assessment by Monotherapy Products, H1 2013
  • Assessment by Combination Products, H1 2013
  • Assessment by Route of Administration, H1 2013
  • Assessment by Stage and Route of Administration, H1 2013
  • Assessment by Molecule Type, H1 2013
  • Assessment by Stage and Molecule Type, H1 2013